Intensive diabetes therapy and body weight: focus on insulin detemir.
Endocrinol Metab Clin North Am
; 36 Suppl 1: 33-44, 2007 Aug.
Article
in En
| MEDLINE
| ID: mdl-17881330
ABSTRACT
Weight gain can be a significant barrier to the treatment of diabetes. Insulin detemir is a basal insulin analog that can help patients move safely toward glycemic targets with less weight gain. This review discusses the potential adverse effects of, and hypothesis for, weight gain resulting from intensive insulin management of diabetes. In addition, an assessment of all weight change data from clinical trials and observational studies involving insulin detemir are presented. Finally, we discuss how the ability of insulin detemir to closely mimic endogenous insulin secretion leads to more predictable glycemic control with reduced weight gain and provides patients with a more acceptable method of achieving glycemic control.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Body Weight
/
Diabetes Mellitus, Type 1
/
Diabetes Mellitus, Type 2
/
Hypoglycemic Agents
/
Insulin
Type of study:
Observational_studies
Limits:
Humans
Language:
En
Journal:
Endocrinol Metab Clin North Am
Journal subject:
ENDOCRINOLOGIA
/
METABOLISMO
Year:
2007
Type:
Article
Affiliation country:
United States